liso-cel

Amidst Legal Battle, BMS' CAR-T Therapy Scores Second FDA Approval
BioSpace
Mon, 06/27/22 - 06:32 pm
Bristol Myers Squibb
CAR-T
Breyanzi
liso-cel
FDA
large B-cell lymphoma
'Major blunder:' Ex-staffers blast Bristol Myers Squibb's handling of Breyanzi approval in latest CVR lawsuit update
Fierce Pharma
Wed, 02/23/22 - 10:09 pm
Bristol Myers Squibb
legal
Breyanzi
shareholders
CAR-T
liso-cel
lymphoma
Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way
Endpoints
Tue, 02/23/21 - 10:58 am
Bristol-Myers Squibb
drug manufacturing
cell therapy
liso-cel
CAR-T
Bristol Myers Squibb's CAR-T liso-cel wins long-delayed FDA nod
Fierce Pharma
Sat, 02/6/21 - 11:23 pm
FDA
Bristol-Myers Squibb
liso-cel
CAR-T
FDA blasts Lonza facility in Form 483 that derailed Bristol Myers' plan of liso-cel nod by 2020
Fierce Pharma
Fri, 01/29/21 - 09:57 am
Bristol-Myers Squibb
Celgene
liso-cel
M&A
CAR-T
Aducanumab tops 2021’s biggest potential launches
EP Vantage
Mon, 01/18/21 - 01:04 pm
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
An FDA inspection raises questions about Bristol Myers Squibb's liso-cel facility and the CVR, but analysts urge caution
Endpoints
Tue, 12/8/20 - 10:41 am
Bristol-Myers Squibb
liso-cel
drug manufacturing
Celgene
CVRs
Could an FDA inspection scupper CVR deadline for BMS’ liso-cel?
Pharmaforum
Fri, 11/6/20 - 09:47 am
Bristol-Myers Squibb
liso-cel
CVRs
JW Therapeutics hauls in $300M IPO just as liso-cel-inspired CAR-T nears the finish line in China
Endpoints
Wed, 11/4/20 - 10:30 am
JW Therapeutics
IPOs
CAR-T
liso-cel
China
Hong Kong
Juno Therapeutics
WuXi AppTec
5 FDA approval decisions to watch in the 4th quarter
BioPharma Dive
Wed, 09/30/20 - 10:45 am
FDA
drug approvals
vaccines
Pfizer
Moderna Therapeutics
COVID-19
Regeneron
EB3
ebola virus
Alkermes
ALKS-3831
schizophrenia
bipolar disorder
Bristol-Myers Squibb
liso-cel
non-Hodgkin lymphoma
roxadustat
FibroGen
chronic kidney disease
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Endpoints
Tue, 03/31/20 - 10:47 am
Bristol-Meyers Squibb
CAR-T
Celgene
ide-cel
Bluebird Bio
liso-cel
ozanimod
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
Mon, 02/17/20 - 11:33 pm
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive
Reuters
Sat, 01/11/20 - 12:06 am
Bristol-Myers Squibb
Celgene
M&A
liso-cel
ozanimod
bb2121
FDA
BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS
Fierce Pharma
Sun, 11/24/19 - 11:35 pm
Bristol-Myers Squibb
Celgene
M&A
ozanimod
liso-cel
bb2121
Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout
Biopharma Dive
Sun, 11/10/19 - 07:56 pm
ASH
Celgene
M&A
Bristol-Myers Squibb
liso-cel
Celgene posts pivotal CAR-T data ahead of FDA filing
Fierce Biotech
Thu, 11/7/19 - 10:28 am
Celgene
CAR-T
liso-cel
Kymriah
Yescarta
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
Motley Fool
Wed, 06/12/19 - 09:45 am
Vertex Pharmaceuticals
VX-445
tezacaftor/ivacaftor
AbbVie
upadacatinib
Daiichi Sankyo
trastuzumab deruxtecan
Celgene
liso-cel
Novartis
LY3298176
Celgene to launch five new products through to 2020
PM Live
Mon, 10/29/18 - 07:02 pm
Celgene
Revlimid
FDA
fedratinib
ozanimod
luspatercept
bb2121
liso-cel
ASCO18: Celgene makes its case as CAR-T rival in lymphoma
Biopharma Dive
Mon, 06/4/18 - 09:34 am
Celgene
JCAR017
liso-cel
CAR-T
B-cell non-Hodgkin lymphoma
ASCO 2018